SEC Form S-8 POS filed by Motus GI Holdings Inc.

$MOTS
Medical/Dental Instruments
Health Care
Get the next $MOTS alert in real time by email
S-8 POS 1 forms-8pos.htm

 

As filed with the Securities and Exchange Commission on August [9], 2024

 

Registration No. 333-271080

Registration No. 333-263940

Registration No. 333-254344

Registration No. 333-237476

Registration No. 333-230506

Registration No. 333-224003

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-271080

Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-263940

Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-254344

Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-237476

Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-230506

Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-224003

 

UNDER THE SECURITIES ACT OF 1933

 

 

MOTUS GI HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware   81-4042793

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

1301 East Broward Boulevard, 3rd Floor

Ft. Lauderdale, FL 33301

(Address of Principal Executive Offices, including Zip Code)

 

Motus GI Holdings, Inc. 2016 Equity Incentive Plan and

2016 Israeli Sub-Plan to the Motus GI Holdings, Inc. 2016 Equity Incentive Plan

(Full titles of the plans)

 

Jeff Varsalone

1301 East Broward Boulevard, 3rd Floor

Ft. Lauderdale, FL 33301

(Name and address of agent for service)

 

(954) 541-8000

(Telephone number, including area code, of agent for service)

 

With copies to:

 

Steven M. Skolnick, Esq.

Lowenstein Sandler LLP

1251 Avenue of the Americas

New York, New York 10020

Telephone: (212) 262-6700

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
       
Non-accelerated filer   Smaller reporting company
       
      Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 

 

 

 

DEREGISTRATION OF SECURITIES

 

These post-effective amendments (the “Post-Effective Amendments”) are being filed by Motus GI Holdings, Inc., a Delaware corporation (the “Company”), to remove from registration all shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and any and all other securities of the Company remaining unissued and unsold under the following Registration Statements on Form S-8 (the “Registration Statements”) filed by the Company with the Securities and Exchange Commission (“SEC”):

 

  Registration Statement No. 333-271080, filed with the SEC on April 3, 2023, pertaining to the registration of an aggregate of 279,586 shares of Common Stock to be issued pursuant to the Motus GI Holdings, Inc. 2016 Equity Incentive Plan and 2016 Israeli Sub-Plan to the Motus GI Holdings, Inc. 2016 Equity Incentive Plan, as amended (the “2016 Plan”);
     
  Registration Statement No. 333-263940, filed with the SEC on March 29, 2022, pertaining to the registration of an aggregate of 2,903,016 shares of Common Stock to be issued pursuant to the 2016 Plan;
     
  Registration Statement No. 333-254344, filed with the SEC on March 16, 2021, pertaining to the registration of an aggregate of 1,936,339 shares of Common Stock to be issued pursuant to the 2016 Plan;
     
  Registration Statement No. 333-237476, filed with the SEC on March 30, 2020, pertaining to the registration of an aggregate of 1,728,665 shares of Common Stock to be issued pursuant to the 2016 Plan;
     
  Registration Statement No. 333-230506, filed with the SEC on March 26, 2019, pertaining to the registration of an aggregate of 1,286,409 shares of Common Stock to be issued pursuant to the 2016 Plan; and
     
  Registration Statement No. 333-224003, filed with the SEC on March 29, 2018, pertaining to the registration of an aggregate of 2,641,250 shares of Common Stock to be issued pursuant to the 2016 Plan.

 

For ease of reference, all share numbers above are as stated in the Registration Statements, without giving pro forma effect to any adjustments, as applicable, for subsequent events such as stock splits occurring after the original filing dates of the respective Registration Statements.

 

In accordance with undertakings made by the Company in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any and all securities of the Company that were registered for issuance that remain unsold at the termination of the offerings, the Company hereby removes from registration any and all securities of the Company registered but unsold under each of the Registration Statements. As a result of this deregistration, no securities remain registered for sale pursuant to the Registration Statements.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ft. Lauderdale, FL, on August [9], 2024.

 

  MOTUS GI HOLDINGS, INC.
     
  By: /s/ Jeff Varsalone
  Name: Jeff Varsalone
  Title: President

 

No other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statements in reliance on Rule 478 of the Securities Act of 1933, as amended.

 

 

 

 

Get the next $MOTS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MOTS

DatePrice TargetRatingAnalyst
1/25/2023Buy → Neutral
Ladenburg Thalmann
More analyst ratings

$MOTS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update

    Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first q

    $MOTS
    Medical/Dental Instruments
    Health Care
  • Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

    Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process to seek strategic partnerships aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueRecent exercise of certain outstanding warrants provided infusion of $2.7M in gross proceeds to the Company, which extended its cash runway into the fourth quarter of 2024 FORT LAUDERDALE, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes a

    $MOTS
    Medical/Dental Instruments
    Health Care
  • EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer

    Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical devi

    $MOTS
    Medical/Dental Instruments
    Health Care

$MOTS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MOTS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MOTS
SEC Filings

See more

$MOTS
Leadership Updates

Live Leadership Updates

See more
  • EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer

    Aldrich's proven commercial, operational and leadership expertise helps position EndoSound for EVS launch and sustainable growth EndoSound™ Inc., a pioneering medical technology company dedicated to advancing patient care, is pleased to announce the appointment of Scott Aldrich Jr as Chief Executive Officer on February 1st, 2024. Mr Aldrich is joining EndoSound from MotusGI (NASDAQ:MOTS) where he served as Vice President of Commercial and Strategy. Stephen Steinberg MD will remain on the executive leadership team as Chief Medical Officer. Mr Aldrich brings operational and commercial leadership abilities paired with extensive experience in interventional gastroenterology and medical devi

    $MOTS
    Medical/Dental Instruments
    Health Care
  • Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors

    FORT LAUDERDALE, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, announced the appointment of Scott Durbin to the Company's Board of Directors (the "Board"). Mr. Durbin has more than 25 years of executive leadership, finance and clinical development experience, including the execution of over $5 billion in financings and merger transactions. In addition, the Company announced that David Hochman and Darren Sherman, independent members of the Board, have stepped down from the Board due to time requirements of their roles as Chief Executive Offi

    $MOTS
    $OBIO
    Medical/Dental Instruments
    Health Care
    Medicinal Chemicals and Botanical Products
  • Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

    Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive Vice President (EVP) of Corporate Development and Strategy role Andrew Taylor joins as Chief Financial Officer (CFO) with over 20 years of CFO experience with emerging growth companies, the last 15 of which were spent in the medical device sector NEW HOPE, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company"))), a biomedical company accelerating high-impact technologies to patients through risk-rewa

    $MOTS
    $OBIO
    Medical/Dental Instruments
    Health Care
    Medicinal Chemicals and Botanical Products

$MOTS
Financials

Live finance-specific insights

See more
  • Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update

    Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (OTCQB:MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the first q

    $MOTS
    Medical/Dental Instruments
    Health Care
  • Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

    The Company continues its exploration process to target strategic and financing alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueThe Company is actively supporting its existing installed customer base and pipeline opportunities in contracted health systems  The Company is advancing its development of Pure-Vu EVS Gastro, designed for Upper GI bleeding procedures, and expects submission to FDA by the end of 2023 FORT LAUDERDALE, Fla., March 31, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and e

    $MOTS
    Medical/Dental Instruments
    Health Care
  • Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update

    Pure-Vu EVS approved for use at 25 hospitals since launch in March 2022, resulting in highest quarterly revenue reported in the Company's historyRecently named a Sole Source Supplier by the Department of Veteran's Affairs, with several VA medical centers executing new contracts for Pure-Vu EVS systems under this designationPresented positive clinical data in three abstracts at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting that further illustrate how Pure-Vu EVS is enabling physicians to significantly improve visualization during colonoscopy procedures across different settings and patient populations FORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSW

    $MOTS
    Medical/Dental Instruments
    Health Care

$MOTS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more